drugset / Trial / NCT05108935
Providing PrEP, Hepatitis C Treatment, and MOUD Through Telemedicine at Greensboro SSP
Completed
17 enrolled
Duke University
Center for AIDS Research (CFAR) · collabNational Institute of Allergy and Infectious Diseases (NIAID) · collab
NaSingle-groupOpen-labelHealth-services research
Summary
The purpose of this study is to provide medication for opioid use disorder (MOUD) with buprenorphine and naloxone, or bup/nx, pre-exposure prophylaxis (PrEP) for HIV prevention, and/or hepatitis C treatment for persons who inject opioids accessing syringe services programs (SSPs), as part of a comprehensive harm reduction program, and assess the acceptability and feasibility of using telemedicine to implement the program. The initial visit will be conducted in person or remotely via telemedicine given COVID-19 protocols at the SSP site in Greensboro, North Carolina (NC); follow-up visits will be conducted via telemedicine.
Timeline
- Start
- 2022-02-17
- Primary completion
- 2023-03-30
- Completion
- 2023-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Buprenorphine | Other / unclassified | — | — |
| Subject | Tenofovir | Small molecule | — | — |
| Subject | glecaprevir | Other / unclassified | — | — |